REFERENCES
- Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
- Wolff R, Clar C, Lerch C, Kleijnen J. Epidemiologie von nicht tumorbedingten chronischen Schmerzen in Deutschland. Schmerz. 2011;25:26–44.
- Muller-Schwefe G, Uberall MA. Schmerz und Lebensqualität. Gesundheitsökonomie & Qualitätsmanagement. 2011;16:S20–S22.
- Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review of randomized trials of long-term opioid mangement for chronic non-cancer pain. Pain Physician. 2011;14:91–121.
- Electronic Medicines Compendium. Palexia SR 50 mg prolonged-release tablets. Summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/ 24389/SPC/Palexia+SR+50+mg+prolonged-release+tablets./ Accessed November 29, 2012.
- Tzschentke TM, Christoph T, Schroder W, [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. Schmerz. 2011;25:19–25.
- Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14:781–783.
- Afilalo M, Etropolski MS, Kuperwasser B, Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Invest. 2010;30:489–505.
- Buynak R, Shapiro DY, Okamoto A, Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11:1787–1804.
- Lange B, Kuperwasser B, Okamoto A, Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27:381–399.
- Schwartz S, Etropolski M, Shapiro DY, Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–162.
- Wild JE, Grond S, Kuperwasser B, Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416–427.
- Merker M, Dinges G, Koch T, Kranke P, Morin AM. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. Schmerz. 2012;26:16–26.
- Steigerwald I, Muller M, Davies A, Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28:911–936.
- Grünenthal GmbH. Fachinformation Palexia® retard. Stand: August 2010.
- Dworkin RH, Turk DC, Wyrwich KW, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9: 105–121.
- Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4:443–453.
- Fine PG, Portenoy RK. Ad hoc expert panel on evidence review and guidelines for opioid rotation: establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418–425.
- Freye E. Opioide In der Medizin. 8. Auflage. Berlin and Heidelberg: Springer; 2009:S, 144–145.